{
    "root": "b90a8c09-6398-4e04-98b7-6a589e2523b2",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Sertraline Hydrochloride",
    "value": "20250519",
    "ingredients": [
        {
            "name": "SERTRALINE HYDROCHLORIDE",
            "code": "UTI8907Y6X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_9124"
        },
        {
            "name": "ANHYDROUS DIBASIC CALCIUM PHOSPHATE",
            "code": "L11K75P92J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_77635"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE (1600000 WAMW)",
            "code": "RFW2ET671P",
            "drugbank_id": "https://go.drugbank.com/drugs/DB00840"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_53426"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "VANILLIN",
            "code": "CHI530446X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_18346"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        }
    ],
    "indications": {
        "text": "sertraline hydrochloride tablets indicated treatment following [ ( 14 ) ] : \u2022major depressive disorder ( mdd ) \u2022obsessive-compulsive disorder ( ocd ) \u2022panic disorder ( pd ) \u2022posttraumatic stress disorder ( ptsd ) \u2022social anxiety disorder ( sad ) \u2022premenstrual dysphoric disorder ( pmdd )",
        "doid_entities": [
            {
                "text": "depressive disorder (DOID:1596)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1596"
            },
            {
                "text": "ocd (DOID:84)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_84"
            },
            {
                "text": "ptsd (DOID:2055)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2055"
            },
            {
                "text": "anxiety (DOID:2030)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2030"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "obsessive-compulsive disorder",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_C052"
            }
        ]
    },
    "contraindications": {
        "text": "indication starting maximum mdd ( 2.1 ) 50 mg per day 200 mg per day ocd ( 2.1 ) 25 mg per day ( ages 6 12 ) 200 mg per day 50 mg per day ( ages \u2265 13 ) pd , ptsd , sad ( 2.1 ) 25 mg per day 200 mg per day pmdd ( 2.2 ) continuous dosing 50 mg per day 150 mg per day pmdd ( 2.2 ) intermittent dosing 50 mg per day luteal phase 100 mg per day luteal phase \u2022 inadequate response starting , titrate 25 50 mg per day increments weekly mdd , ocd , pd , ptsd , sad ( 2.1 ) \u2022 full prescribing information titration pmdd ( 2.2 ) \u2022 hepatic impairment : mild : recommended starting maximum half recommended ( 2.4 ) moderate severe : recommended ( 2.4 ) \u2022 discontinuing sertraline hydrochloride tablets , reduce dose gradually ( 2.6 , 5.4 )",
        "doid_entities": [
            {
                "text": "ocd (DOID:84)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_84"
            },
            {
                "text": "ptsd (DOID:2055)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2055"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "sertraline hydrochloride tablets usp , 50 mg blue colored , capsule shaped , biconvex , film-coated tablets , debossed ' l ' ' u ' either side breakline one side 'd02 ' side . overbagged 10 film-coated tablets per bag , ndc 55154-3569-0 sertraline hydrochloride tablets usp , 100 mg yellow colored , capsule shaped , biconvex , film-coated tablets , debossed ' l ' ' u ' either side breakline one side 'd03 ' side . overbagged 10 film-coated tablets per bag , ndc 55154-3570-0 warning : unit dose packages child resistant intended institutional . keep drugs reach children . store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) [ usp controlled room temperature ] .",
    "adverseReactions": "sertraline hydrochloride tablets contraindicated patients : \u2022taking , within 14 days stopping , maois , ( including maois linezolid intravenous methylene blue ) increased risk serotonin syndrome [ ( 5.2 ) , ( 7.1 ) ] . \u2022taking pimozide [ ( 7.1 ) ] . \u2022with known hypersensitivity sertraline ( e.g . , anaphylaxis , angioedema ) [ ( 6.1 , 6.2 ) ] .",
    "indications_original": "Sertraline hydrochloride tablets are indicated for the treatment of the following [See Clinical Studies (14)]:\n                  \n                     \n                        \u2022Major      depressive disorder (MDD)\n                     \n                        \u2022Obsessive-compulsive      disorder (OCD)\n                     \n                        \u2022Panic disorder      (PD)\n                     \n                        \u2022Posttraumatic      stress disorder (PTSD)\n                     \n                        \u2022Social anxiety      disorder (SAD)\n                     \n                        \u2022Premenstrual dysphoric disorder (PMDD)",
    "contraindications_original": "Indication Starting Dosage Maximum Dosage MDD (2.1) 50 mg per day 200 mg per day OCD (2.1) 25 mg per day (ages 6 to 12) 200 mg per day 50 mg per day (ages \u2265 13) PD, PTSD, SAD (2.1) 25 mg per day 200 mg per day PMDD (2.2) continuous dosing 50 mg per day 150 mg per day PMDD (2.2) intermittent dosing 50 mg per day during luteal phase only 100 mg per day during luteal phase only \u2022 If inadequate response to starting dosage, titrate in 25 to 50 mg per day increments once weekly in MDD, OCD, PD, PTSD, and SAD ( 2.1 ) \u2022 See Full Prescribing Information for titration in PMDD ( 2.2 ) \u2022 Hepatic impairment: o Mild: Recommended starting and maximum dosage is half recommended dosage ( 2.4 ) o Moderate or severe: Not recommended ( 2.4 ) \u2022 When discontinuing sertraline hydrochloride tablets, reduce dose gradually ( 2.6 , 5.4 )",
    "warningsAndPrecautions_original": "Sertraline Hydrochloride Tablets USP, 50 mg\n                  \n                  Blue colored, capsule shaped, biconvex, film-coated tablets, debossed with 'L' and 'U' on either side of the breakline on one side and 'D02' on the other side.\n                  Overbagged with 10 film-coated tablets per bag,\u00a0NDC 55154-3569-0\n                  \n                     Sertraline Hydrochloride Tablets USP, 100 mg\n                  \n                  Yellow colored, capsule shaped, biconvex, film-coated tablets, debossed with 'L' and 'U' on either side of the breakline on one side and 'D03' on the other side.\n                  Overbagged with 10 film-coated tablets per bag, NDC 55154-3570-0\n                  WARNING: These Unit Dose packages are not child resistant and are Intended for Institutional Use Only. Keep this and all drugs out of the reach of children.\n                  Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F) [See USP Controlled Room Temperature].",
    "adverseReactions_original": "Sertraline hydrochloride tablets are contraindicated in patients:\n                  \n                     \n                        \u2022Taking, or within 14 days of      stopping, MAOIs, (including the MAOIs linezolid and intravenous methylene      blue) because of an increased risk of serotonin syndrome [See Warnings      and Precautions (5.2), Drug Interactions (7.1)] .\n                     \n                        \u2022Taking pimozide [See Drug      Interactions (7.1)].\n                     \n                     \n                        \u2022With known      hypersensitivity to sertraline (e.g., anaphylaxis, angioedema) [See      Adverse Reactions (6.1, 6.2)] .",
    "drug": [
        {
            "name": "Sertraline Hydrochloride",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_9124"
        }
    ]
}